Compare Ishares Msci Brazil ETF (EWZ) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs McKesson Corporation — how do they compare? Ishares Msci Brazil ETF trades at $35.46, while McKesson Corporation trades at $817.94 (market cap $93.23B). The key difference: McKesson Corporation pays a 0.41% dividend while Ishares Msci Brazil ETF pays none, and Ishares Msci Brazil ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| EWZ | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $995.69 |
52-Week Low | $26.52 | $659.01 |
Market Cap | — | $93.23B |
Enterprise Value | — | $97.87B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ (iShares MSCI Brazil ETF) trades at $35.365, down 1.85% today but maintains a bullish technical outlook with 15 buy signals versus 4 sell signals. The ETF has gained approximately 11% year-to-date, benefiting from Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's $9.92 billion Eco Invest auction and export regulation adjustments to meet EU requirements, supporting economic momentum.
The outlook for EWZ remains positive as Brazil's central bank continues rate cuts from historically high levels, creating favorable conditions for equities. Key risks include dependency on commodity prices and potential economic volatility. Analyst sentiment leans bullish with expectations of further upside from monetary policy support and attractive valuations in Brazilian markets.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
